The Relationship Between Drug Price Controls And Patient Health Outcomes
This white paper will review the published evidence on the relationship between drug price controls and patient health outcomes.

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service researchers, biopharma industry representatives, and healthcare professionals. However, the “quick and easy fix” option of price controls invariably comes up. While this option is publicly appealing, the question is what (if any) unintended effects might occur from enacting drug price controls? This white paper will review the published evidence on the relationship between drug price controls and patient health outcomes, especially given the importance of the pharmaceutical industry and drug innovation to the overall social well-being of society.
Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.
Contact us at insights@axtria.com for any questions.
Complete the brief form to download the white paper
Recommended insights

Blog
MedTech as a Service: How Subscription-Based Selling Will Play a Role in the Future of MedTech

Blog
The importance of measuring the impact of specialized pharmaceutical sales reps on patient outcomes

Case Study